文章目录

CAPTURE研究

原文发布日期：2021-10-27

英文摘要：

摘要翻译：

原文链接：

文章：

CAPTURE研究

the CAPTURE study

原文发布日期：2021-10-27

英文摘要：

Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.

摘要翻译：

COVID-19 病毒 (SARS-CoV-2) 抗病毒应答在一项全面肿瘤免疫监测试验（CAPTURE）中是一项前瞻性队列研究，旨在评估患有癌症的患者的 COVID-19 免疫情况。在这里我们评估了接受两剂 BNT162b2 或 AZD1222 疫苗接种的 585 例患者，疫苗接种间隔 12 周。针对固体瘤和血液系统恶性肿瘤患者的血清转换率分别为 85% 和 59%。相对于 SARS-CoV-2 原发型（VOC）和野生型（WT），接受两剂疫苗的患者中和抗体（NAbT）检测到特异性强 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 变种的比例较低。血液系统恶性肿瘤患者的 NAbT 未检出，且 NAbT 的中位数低于固体瘤癌症患者的 SARS-CoV-2 WT 和 VOC。与无癌患者相比，血液系统但非固体瘤恶性肿瘤患者的中和抗体（NAb）反应较低。血清转换与针对 VOC 的中和抗体检测结果不符。既往 SARS-CoV-2 感染增强包括针对 VOC 的中和抗体应答，而抗 CD20 处理与未检出 NAbT 有关。疫苗诱导的 T 细胞反应在 80% 的患者中检测到，并且在疫苗类型或肿瘤类型之间具有可比性。我们的结果为目前正在进行的 COVID-19 流行期间癌症患者的管理提供了指导意义。